Myanmar-Oxford Clinical Research Unit (MOCRU)

Significant research achievements at MOCRU 2009-2014

In the waiting area at Hlaingthayar Clinic
  1. Compared the effectiveness of five ACT regimens with and without primaquine, showing that artesunate-amodiaquine should not be used in Myanmar due to high failure rate, and that single-dose primaquine significantly reduced transmission potential (Figure 10)
  2. Conducted a cluster-randomised study of the effectiveness of insecticide treated bednets in Yangon, Myanmar) western Myanmar, showing incomplete protection of children in malaria endemic villages
  3. Studied the entomological determinants of effectiveness of insecticide treated bednets, showing that in western Cambodia peak vector biting occurred outdoors early in the evening – explaining the limited effectiveness of bednets
  4. Conducted the Tracking Resistance to Artemisinin (TRAC) study in 4 sites, helping to define the spread of artemisinin resistance and relating Kelch 13 genotype to phenotype
  5. Mapping Artemisinin resistance (Kelch 13 mutations) in Myanmar through the work of of 15 survey teams across Myanmar
  6. Initiated a study in Kayin state comparing 3 days vs 5 days of artemether-lumefantrine for the treatment of artemisinin resistant malaria
  7. Contributed to pooled analyses of the safety and efficacy of dihydroartemisinin-piperaquine in the treatment of uncomplicated malaria
  8. Studied the effectiveness of giving 1g fish oil with artemether-lumefantrine doses to improve absorption
  9. Reported on the screening of HIV patients for CMV retinitis, and practical treatment using intravitreous ganciclovir injection in a resource-poor setting where systemic anti-CMV therapy was not available
  10. Demonstrated the high mortality associated with a diagnosis of CMV mortality retinitis in the absence of systemic anti-CMV therapy